Literature DB >> 7643746

Whole blood model of meningococcal bacteraemia--a method for exploring host-bacterial interactions.

C A Ison1, R S Heyderman, N J Klein, M Peakman, M Levin.   

Abstract

An ex vivo whole blood model of meningococcal bacteraemia was developed to examine the total bactericidal activity of blood. Using a single defined donor and strains belonging to serogroups A, B and C and an unencapsulated strain, we demonstrated that the bactericidal mechanisms operating in whole blood varied with anticoagulant, serogroup and bacterial growth conditions. The choice of anticoagulant had a major effect on the survival of the serogroup A strain with 94% (SEM 7.6) survival in citrated blood compared to 19.7% (SEM 19.6) survival in heparinised blood after 60 min incubation. The serogroup C strain showed enhanced survival when grown in liquid medium compared to growth on solid medium (73.5%, SEM 7.5, and 8.2%, SEM 3.1, respectively, in citrated blood after 60 min). The pattern of survival of serogroup B and the unencapsulated strain were largely unaffected by these variables. Comparison with cell free conditions allowed the contribution of cellular components in meningococcal killing to be determined. Secreted levels of tumour necrosis factor and neutrophil elastase secreted during whole blood assays did not correlate with bacterial growth or viability indicating a lack of relationship between killing and activation of phagocytes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7643746     DOI: 10.1016/s0882-4010(95)90093-4

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  15 in total

1.  Bactericidal activity against coagulase-negative staphylococci is impaired in infants receiving long-term parenteral nutrition.

Authors:  Y Okada; N J Klein; H K van Saene; G Webb; H Holzel; A Pierro
Journal:  Ann Surg       Date:  2000-02       Impact factor: 12.969

2.  Stereotyped and specific gene expression programs in human innate immune responses to bacteria.

Authors:  Jennifer C Boldrick; Ash A Alizadeh; Maximilian Diehn; Sandrine Dudoit; Chih Long Liu; Christopher E Belcher; David Botstein; Louis M Staudt; Patrick O Brown; David A Relman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

3.  A Neisseria meningitidis NMB1966 mutant is impaired for invasion of respiratory epithelial cells, survival in human blood and for virulence in vivo.

Authors:  Ming-Shi Li; Noel Y S Chow; Sunita Sinha; Denise Halliwell; Michelle Finney; Andrew R Gorringe; Mark W Watson; J Simon Kroll; Paul R Langford; Steven A R Webb
Journal:  Med Microbiol Immunol       Date:  2008-12-03       Impact factor: 3.402

4.  Seroprevalence of Antibody-Mediated, Complement-Dependent Opsonophagocytic Activity against Neisseria meningitidis Serogroup B in England.

Authors:  Holly E Humphries; Charlotte Brookes; Lauren Allen; Eeva Kuisma; Andrew Gorringe; Stephen Taylor
Journal:  Clin Vaccine Immunol       Date:  2015-03-04

5.  Anticoagulants impact on innate immune responses and bacterial survival in whole blood models of Neisseria meningitidis infection.

Authors:  Lea Strobel; Kay O Johswich
Journal:  Sci Rep       Date:  2018-07-05       Impact factor: 4.379

6.  Gram-negative bacteria induce proinflammatory cytokine production by monocytes in the absence of lipopolysaccharide (LPS).

Authors:  H Uronen; A J Williams; G Dixon; S R Andersen; P Van Der Ley; M Van Deuren; R E Callard; N Klein
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

7.  Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal antibody.

Authors:  Jo Anne Welsch; Dan Granoff
Journal:  Clin Vaccine Immunol       Date:  2007-10-03

8.  Analysis of the regulated transcriptome of Neisseria meningitidis in human blood using a tiling array.

Authors:  Elena Del Tordello; Silvia Bottini; Alessandro Muzzi; Davide Serruto
Journal:  J Bacteriol       Date:  2012-09-14       Impact factor: 3.490

Review 9.  Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease.

Authors:  Dan M Granoff
Journal:  Vaccine       Date:  2009-05-23       Impact factor: 3.641

10.  Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity.

Authors:  Joyce S Plested; Jo Anne Welsch; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2009-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.